Sialylated HMO Branch
3'-SL adds a sialylated structure to a portfolio that may already contain fucosylated and neutral HMOs. It is useful when the nutrition company wants a complete HMO-family story.
3'-Sialyllactose Sodium Salt gives technical teams a sialylated HMO option for advanced nutrition projects. Nutrition companies often review it with 6'-SL when they want a broader sialylated portfolio or a more complete HMO family range.
Nutrition companies usually review assay basis, sodium contribution, impurity profile, moisture, and microbiology before sampling or commercial formulation.
Fermentation-Based HMOApplication and Regulatory Review
Review 3'-SL application direction, use-level references, permitted categories, labelling points, and destination-market requirements before sampling, quotation, or commercial formulation.
3'-SL adds a sialylated structure to a portfolio that may already contain fucosylated and neutral HMOs. It is useful when the nutrition company wants a complete HMO-family story.
The six-HMO comparison gives 3'-SL a clear R&D angle. We use it for screening and formulation discussion, not for disease prevention or treatment claims.
3'-SL can be discussed for specialty nutrition projects where the target population, dosage, sodium contribution, and document requirements need careful review.
3'-SL pairs naturally with 6'-SL when nutrition companies want sialylated HMO coverage or a multi-HMO blend with acidic HMO components.
EU 2021/96 authorises 3'-SL sodium salt as a novel food, and EU 2024/1047 gives a newer source-specific 3'-SL sodium salt authorisation. Nutrition companies should also review same-day-use and age-group labelling requirements.
The FDA GRAS Notice Inventory includes 3'-SL sodium salt entries with 'no questions' response letters, including GRN 766, GRN 880, GRN 921, GRN 1015, GRN 1052, GRN 1074, and GRN 1299. GRN 1299 provides a current 2026 reference for formula and young-child foods.
Technical Data
| Color | White to off-white |
|---|---|
| Appearance | Powder |
| 3'-Sialyllactose Sodium Salt (Water-Free) | >=88.0% |
| N-Acetylneuraminic Acid | <=1.5% |
| 3'-Sialyllactulose | <=5.0% |
| D-Lactose | <=3.0% |
| Moisture | <=10.5% |
| Sodium | <=4.2 x 10^3 mg/100 g |
| Residual Protein | <=100 mg/kg |
| Endotoxins | <=10 EU/mg |
| Total Arsenic | <=0.1 mg/kg |
| Lead | <=0.05 mg/kg |
| Total Plate Count | <=500 CFU/g |
| Enterobacteriaceae | <10 CFU/g |
| Salmonella | Absent in 25 g |
Project Support
Share your specification target, annual forecast, and market requirements. We will help check supply options, sample route, and application direction.